Bronchial Asthma in Pregnancy

Definition and Prevalence

Physiological Background in Pregnancy

Effect of Pregnancy on Asthma (the "Rule of Thirds")

• ~1/3 improve
• ~1/3 worsen
• ~1/3 remain unchanged

• Pregnancy-associated changes in sex hormone levels
• Psychosocial stress
• Nonadherence to medications
• Higher prevalence of GERD
• Nasal congestion
• Altered immunity
• Respiratory infections

Effect of Asthma on Pregnancy (Maternal and Fetal Complications)

• Preeclampsia (increased risk)
• Gestational diabetes
• Ante- and postpartum hemorrhage
• Anemia
• Depression
• Preterm labour

• Preterm birth (spontaneous and induced)
• Small for gestational age (SGA)
• Low birthweight (<2500 g)
• Congenital anomalies (increased risk)
• Perinatal mortality (in severe, uncontrolled cases)

Diagnosis in Pregnancy

• Most patients have a pre-existing history of asthma
• Differential diagnosis: Dyspnea of pregnancy (no wheezing/cough/obstruction), pulmonary embolism, pulmonary edema, COPD, laryngeal dysfunction, hyperventilation
• Confirmed by: FEV1 reduced with at least 12% or 200 mL improvement after inhaled albuterol
• Methacholine challenge is contraindicated in pregnancy
• Exhaled nitric oxide (FeNO) is significantly elevated in pregnant asthmatics vs. healthy pregnant controls - useful marker
• Skin testing for allergies is not recommended (risk of systemic reactions); specific IgE blood testing is preferred

Management

• Minimal or no maternal symptoms day or night
• No limitations of activities
• Maintenance of normal or near-normal pulmonary function
• Minimal use of rescue bronchodilators

1. Objective Assessment and Monitoring

• Spirometry is the preferred method; PEFR is an acceptable alternative
• Normal PEFR in pregnancy: 380-550 L/min
• PEFR zones: Green >80%, Yellow 50-80%, Red <50% of personal best
• Patients with moderate-severe asthma should have daily PEFR monitoring
• FEV1 <80% predicted is associated with preterm birth and low birthweight

2. Trigger Avoidance

• Avoid allergens: house dust mites, animal dander, cockroach antigens, mold, pollens
• Avoid tobacco smoke (active and passive)
• Control GERD
• Avoid NSAIDs/aspirin and beta-blockers in sensitive patients
• Exercise-induced asthma: pre-treat with albuterol inhaler 10-15 minutes before exercise

3. Patient Education

• Action plans (green/yellow/red zones)
• Proper inhaler technique
• Emphasis that medication risks are lower than the risk of uncontrolled asthma
• Symptom monitoring and self-management

4. Pharmacologic Therapy

• Albuterol (salbutamol): Drug of choice for acute relief; well-established safety profile
• Budesonide (ICS): Preferred ICS in pregnancy due to most safety data; ICS is the cornerstone of treatment for ALL levels of persistent asthma in pregnancy
• Salmeterol/formoterol (LABA): Safe in combination with ICS; do not use as monotherapy
• Theophylline: Acceptable in moderate-severe asthma; monitor serum levels (therapeutic 5-12 mcg/mL); crosses placenta - can cause neonatal irritability/tachycardia
• Systemic corticosteroids (oral/IV): Benefits outweigh risks in acute exacerbations; associated with cleft palate (first trimester exposure), gestational diabetes, preeclampsia when used long-term
• Montelukast (LTRA): Use with caution (FDA warning - possible association with congenital anomalies); may be needed if asthma cannot be controlled otherwise
• Ipratropium bromide: Safe; added to albuterol in acute exacerbations
• Biologic agents (omalizumab, etc.): Limited fetal safety data; as IgG molecules, expected to cross placenta in 2nd trimester; use only when clearly needed

Management of Acute Exacerbation in Pregnancy

• Supplemental O2 to maintain SpO2 >95%
• Nebulized albuterol 2.5 mg every 20 minutes for 3 doses
• Fetal monitoring (CTG if viable)

Fetal Surveillance

• Serial ultrasound for fetal growth in moderate-severe or poorly controlled asthma
• Antepartum fetal surveillance (NST/biophysical profile) starting at 32 weeks for moderate-severe asthma
• After recovery from a severe exacerbation

Labor and Delivery

• Asthma attacks are uncommon during labor (high endogenous cortisol and prostaglandins E2 may be protective)
• Stress-dose corticosteroids should be given to patients on prolonged systemic steroids during labor
• Regional anesthesia is preferred (reduces minute ventilation, O2 consumption, prevents hyperinflation)
• If general anesthesia required: ketamine and halogenated agents are preferred (bronchodilatory)
• Safe oxytocics: Oxytocin and prostaglandin E2
• Avoid: Prostaglandin F2-alpha (carboprost), morphine, meperidine, ergometrine - all may trigger bronchospasm

Preconceptional Counseling

• Consult pulmonologist/allergist/MFM specialist before conception
• Baseline pulmonary function testing
• Optimize asthma control before conception
• Stop smoking; avoid triggers
• Continue asthma medications during pregnancy
• Reassure: well-controlled asthma = excellent pregnancy outcomes

Summary

Pulmonary Tuberculosis in Pregnancy

Introduction and Epidemiology

Effect of Pregnancy on TB

• Fatigue and malaise of early TB can be confused with symptoms of normal pregnancy
• Physiological dyspnoea in pregnancy may mask respiratory symptoms
• A high index of suspicion is essential

Effects of TB on Pregnancy (Complications)

• Severe preeclampsia and eclampsia
• Placenta previa
• Postpartum hemorrhage
• Sepsis
• Anemia
• Higher morbidity and mortality (if untreated)
• TB-positive women have an 80% increased rate of pregnancy complications compared to TB-negative women

• Intrauterine growth restriction (IUGR)
• Preterm birth (spontaneous and induced)
• Low birthweight
• Perinatal mortality
• Congenital tuberculosis (rare but documented)

Routes of Fetal Transmission (Congenital TB)

1. Hematogenous spread through the placenta (most common)
2. Contiguous spread from endometrial tuberculosis
3. Aspiration of TB-infected amniotic fluid

High-Risk Factors for TB in Pregnancy (Box 58.1)

• HIV infection / immunosuppression
• Close contact with known/suspected TB cases
• Birth in a high-prevalence country
• Medically underserved or low-income status
• Alcohol addiction / IV drug use
• Residency in a long-term care facility (prison, nursing home)
• Healthcare workers in high-risk facilities

Diagnosis

Symptoms of Active TB

• Cough (74%)
• Weight loss (41%)
• Fever (30%)
• Malaise and fatigue (30%)
• Hemoptysis (19%)

Screening Tests

1. Tuberculin Skin Test (TST/Mantoux): Subcutaneous injection of purified protein derivative (PPD); sensitivity 90-99%; safe in pregnancy; interpretation: ≥10 mm induration is significant (in high-risk groups, ≥5 mm)
2. Interferon-Gamma Release Assay (IGRA/QuantiFERON-TB): In vitro blood test; specificity >95%; results in 24-48 hours; no follow-up visit required; not affected by BCG vaccination status. Note: Both TST and IGRA detection rates may be impacted by pregnancy, and different cut-offs may be needed.

Confirmatory Tests for Active Disease

• Chest radiograph (essential; with abdominal shielding): perform after first trimester in asymptomatic PPD-positive women; perform immediately if symptomatic

Radiographic findings of pulmonary TB:

Chest X-ray of pulmonary TB: adenopathy, multinodular infiltrates, cavitation, loss of volume in upper lobes, upper medial retraction of hilar markings (Creasy & Resnik, Fig. 58.8)

• AFB smear microscopy: At least 3 early-morning sputum samples; if sputum cannot be produced - sputum induction, gastric washings, or bronchoscopy
• Nucleic acid amplification tests (NAAT): MTD Test and Amplicor MTB Test - amplify M. tuberculosis 16S ribosomal DNA; sensitivity and specificity of 95% and 100% in smear-positive specimens
• Placental and endometrial biopsy at delivery if congenital TB is suspected (but workup must never be delayed until delivery)

Management

Latent TB Infection (LTBI) in Pregnancy

• Treatment may be deferred to postpartum in women at low risk for reactivation (unknown or prolonged PPD positivity >2 years)
• Immediate treatment is indicated in:
  • HIV co-infected women (risk of reactivation is significant)
  • Women with recent TB contact/conversion
  • High-risk patients

Active TB in Pregnancy - Treatment

Drug Safety Profile in Pregnancy

MDR-TB in Pregnancy

• MDR-TB (resistant to INH + RIF) complicates management significantly
• Many second-line drugs are contraindicated
• Directly observed therapy (DOT) is strongly recommended
• Patient must be counselled about small risk of teratogenicity
• Management must be individualized by a specialist team
• Second-line injectable agents (streptomycin, capreomycin, kanamycin) are all best avoided

Fetal Surveillance

• Serial ultrasound for fetal growth assessment
• Antepartum surveillance for fetal well-being in severe/active disease
• Neonatal evaluation at birth if maternal active TB is present

Labor and Delivery

• Uncomplicated TB is not an indication for cesarean section
• Mother with active (infectious) TB should wear a mask during labor
• Neonates born to mothers with active TB:
  • Evaluate for congenital TB
  • Should not be routinely separated from mother if mother on treatment for >2 weeks
  • Give isoniazid prophylaxis to the neonate; BCG vaccination after completion of INH prophylaxis
  • Monitor for neonatal TB symptoms in the first 90 days

Breastfeeding

• Breastfeeding should not be discouraged in women being treated for TB, unless the mother is still infectious (sputum AFB positive)
• Anti-TB drugs are secreted in breast milk in small concentrations (not therapeutic for the infant but potentially additive if the neonate is also on treatment)
• Transmission of mycobacteria via breast milk is very unlikely, except in rare cases of TB mastitis

Prevention

• BCG vaccination (all neonates in endemic areas)
• Active case finding and contact tracing
• IGRA/PPD screening of all high-risk pregnant women
• Directly observed therapy (DOT) for adherence
• HIV testing in all TB cases (and vice versa)
• Adequate nutrition and social support

Summary

Prolapse Uterus Complicating Pregnancy

Definition

Incidence

• Developing countries (India, Africa, Middle East)
• Grand multiparae
• Rural populations with poor obstetric care
• Women with connective tissue disorders

Classification / Degrees of Prolapse

Aetiology and Predisposing Factors

Pre-existing (before pregnancy):

• Grand multiparity with inadequate perineal repair
• Previous difficult/prolonged labour and delivery
• Pelvic floor injury from prior obstetric trauma
• Inherent connective tissue weakness (Ehlers-Danlos syndrome, Marfan syndrome)
• Congenital weakness of supporting ligaments

Pregnancy-related factors (aggravating):

• Cervical elongation, hypertrophy due to increased vascularity
• Ligamentous relaxation from progesterone and relaxin - these hormones soften and relax the cardinal and uterosacral ligaments
• Increased intra-abdominal pressure (especially with twin pregnancy, polyhydramnios)
• Aggravation of pre-existing prolapse by the gravid uterus

Natural course during pregnancy:

• As the uterus enlarges beyond the 1st trimester, it rises out of the pelvis and is supported by the pelvic brim - this naturally reduces the degree of prolapse in many cases
• However, the elongated, oedematous cervix may continue to protrude even after the body of the uterus has risen

Effects of Prolapse on Pregnancy (Complications)

Early Pregnancy (1st Trimester):

• Spontaneous abortion (miscarriage) - increased risk due to poor vascularity, infection, and physical factors
• Difficulty conceiving (though conception can occur even with significant prolapse)

During Pregnancy (2nd & 3rd Trimester):

• Cervical desiccation and ulceration - exposed cervix undergoes ulceration, secondary infection; increases risk of ascending infection
• Urinary tract infections (UTI) and urinary retention - common; bladder neck distortion causes voiding dysfunction
• Acute urinary retention - may require catheterization; this is a serious and recurrent complication
• Preterm labour - due to infection (chorioamnionitis), cervical incompetence, or physical stimulation of the prolapsed cervix
• Maternal and fetal sepsis - from ascending infection through the ulcerated, exposed cervix
• Incarceration of the gravid uterus - retroversion with entrapment behind the sacral promontory; a related but distinct complication
• Maternal discomfort, pressure sensation, difficulty walking
• Preterm premature rupture of membranes (PPROM)

During Labour:

• Obstruction of labour - prolapsed, oedematous, rigid cervix may fail to dilate normally
• Cervical dystocia - oedematous prolapsed cervix may not efface and dilate
• Cord prolapse - if membranes rupture with presenting part not engaged
• Postpartum haemorrhage - due to uterine atony from prolonged labour

Maternal Outcome:

• Increased maternal morbidity
• Rare cases of maternal death (from sepsis, obstructed labour)

Fetal Outcome:

• Increased perinatal mortality
• Prematurity
• Fetal growth restriction
• Neonatal sepsis

Clinical Features

• Symptoms: Feeling of something coming down the vagina, dragging/pressure sensation in the pelvis, difficulty walking, dysuria, urinary retention, vaginal discharge (from cervical ulceration/infection), recurrent UTI
• Signs: On examination - cervix/uterus visible or palpable at or beyond the introitus; cervical oedema, hypertrophy, elongation; ulceration/inflammation of exposed cervix; positive gravid uterus on bimanual examination (if 1st/2nd trimester)

Management

• Gestational age at presentation
• Degree of prolapse
• Presence of complications (ulceration, urinary retention, infection)
• Patient's desire to continue the pregnancy
• Available resources

Conservative Management (First-line)

• Knee-chest position or Trendelenburg position to reduce the prolapse by gravity
• Rest reduces prolapse aggravated by upright posture and straining

• Gentle digital reduction of the prolapsed uterus with the patient in Trendelenburg position
• Regular reduction and maintenance

• Vaginal ring pessary (with or without support, Hodge pessary) is the most practical conservative measure
• Provides mechanical support to the uterus and prevents re-prolapse
• First reported in pregnancy in 1949; remains the most valuable non-invasive option
• Silicone-coated ring pessary is preferred - easy insertion, patient self-care possible
• Changed or cleaned every 2-4 weeks; monitor for pressure ulcers
• Effective until about 14-16 weeks, after which the enlarging uterus rises out of the pelvis naturally

• Local antiseptic/oestrogen cream for cervical ulceration
• Antibiotics for superadded infection or UTI
• Urinary catheterization for urinary retention (indwelling catheter if needed)
• Maintain good perineal hygiene

• In cases with associated cervical incompetence
• Helps retain pregnancy to viable gestational age
• Performed in 2nd trimester (14-16 weeks)

Surgical Management

• Failed conservative management
• Severe prolapse not reducible
• Recurrent urinary retention unresponsive to conservative measures
• Severe ulceration and cervical necrosis

• Laparoscopic uterine suspension (sacrohysteropexy): Most evidence from case reports; performed typically in early 2nd trimester (13-16 weeks) when the risk of pregnancy loss is lowest; preserves uterus and pregnancy
• Pelvic floor repair procedures: Generally deferred postpartum

• Avoid 1st trimester (high miscarriage risk)
• Early 2nd trimester is the safest window if surgery is necessary

Management During Labour and Delivery

Mode of Delivery:

• Vaginal delivery is possible and preferred if:
  • Cervix dilates adequately
  • No obstruction to labour
  • Fetal presentation is cephalic
• Caesarean section (LSCS) is indicated for:
  • Failed progress / cervical dystocia (oedematous, non-dilating cervix)
  • Cord prolapse
  • Fetal distress
  • Severe cervical ulceration, infection, or oedema preventing vaginal delivery
  • Obstetric indications (malpresentation, CPD)
  • Most modern authorities favour LSCS to avoid further pelvic floor trauma

Intraoperative precautions:

• Be alert for urinary tract involvement (bladder, ureter injury) due to distorted anatomy
• Careful haemostasis

After Delivery:

• Uterine prolapse often reduces spontaneously after delivery as the uterus involutes
• However, the pelvic floor damage may worsen with each subsequent vaginal delivery
• Surgical repair (pelvic floor reconstruction, colporrhaphy, pelvic floor repair) is best planned 3-6 months postpartum after full involution
• Advise against future pregnancies until surgical repair is done

Summary Table

Key Points to Remember (Exam Focus)

1. Uterine prolapse in pregnancy is RARE (1 in 10,000-15,000) but potentially life-threatening
2. The degree appears to reduce spontaneously as pregnancy advances beyond 16 weeks (uterus rises above pelvis)
3. The cervix undergoes hypertrophy and elongation making it protrude even when the uterine body has risen
4. Urinary retention is the most troublesome acute complication
5. Ring pessary is the cornerstone of conservative management
6. Streptomycin-like 2nd line drugs are - never forget progesterone/relaxin are the hormones responsible for ligamentous laxity
7. Surgical repair should be deferred to 3-6 months postpartum
8. Procidentia (3rd degree/complete prolapse) persisting into 3rd trimester is extremely rare

Embryo / Fetal Reduction (Multifetal Pregnancy Reduction - MFPR)

Definition

• Reduce the risks of preterm delivery and associated morbidity/mortality for the surviving fetuses
• Improve the overall chances of a healthy live birth
• Reduce maternal health risks from carrying a high-order multiple pregnancy

Background and Rationale

• 75% of triplets are expected to require NICU admission
• Natural history of triplet gestation: 7-8% risk of delivery between 24-28 weeks, and 11% risk of spontaneous loss before 24 weeks
• Quadruplets: 14% risk of delivery before 28 weeks

Maternal risks of higher order multiple pregnancy:

• Gestational diabetes
• Hypertensive disorders of pregnancy (gestational hypertension, preeclampsia)
• Anemia
• Increased need for cesarean section
• Postpartum haemorrhage
• Maternal mortality

Indications

1. Higher-order multiple pregnancy (triplets and above) - most common indication; all patients with quadruplet+ gestation should be counselled about MFPR
2. Triplet pregnancy - offered with counselling; debate exists but evidence supports it
3. One fetus with a major chromosomal or structural abnormality in a multiple pregnancy (selective feticide)
4. Monochorionic pair in a higher-order multiple (they share circulation, carry greater risk)
5. Maternal medical conditions where multiple pregnancy poses excessive risk
6. Patient choice after informed counselling (for twin pregnancy reduced to singleton - controversial)

Contraindications / Special Considerations

• Monochorionic twins within a higher-order multiple: potassium chloride (KCl) cannot be used because fetocide via KCl in one twin of a monochorionic pair risks death or neurological injury in the co-twin through the shared placental circulation. Alternative methods (radiofrequency ablation, cord coagulation) must be used.
• Ethical concerns - requires thorough pre-procedure counselling

Timing of the Procedure

• Optimal timing: 10-13 weeks of gestation (first trimester)
• At this stage:
  • Crown-rump length (CRL) can be accurately measured
  • Nuchal translucency can be assessed (to select abnormal fetuses for reduction)
  • Spontaneous loss of one or more fetuses (which occurs in 5-10% of higher-order multiples in 1st trimester) has already been accounted for
  • The procedure carries a lower loss rate than in the second trimester
• Performing earlier (before 10 weeks) carries higher loss rates
• Second-trimester MFPR is occasionally performed but carries higher complication rates

Pre-procedure Evaluation

1. Detailed ultrasound to:
   • Count all gestations
   • Determine chorionicity and amnionicity
   • Map placental location
   • Measure CRL and nuchal translucency (NT) of all fetuses
2. Chorionic villus sampling (CVS) - may be performed before MFPR to confirm karyotype
   • CVS of fetuses destined to be retained (to confirm normality)
   • Fetuses with chromosomal abnormalities are preferentially targeted for reduction
   • CVS before MFPR has been shown safe with no increase in loss rate
3. Genetic counselling
4. Informed consent after full discussion of risks, alternatives, and ethical considerations

Technique

Transabdominal Approach (Preferred)

1. Patient is placed supine; no prophylactic antibiotics are routinely given (analogous to CVS/amniocentesis)
2. Detailed ultrasonography maps all gestational sacs, CRL, NT, and abnormalities
3. Target fetus selection:
   • Fetuses with abnormal NT or identified abnormality are selected first
   • Otherwise, the fetus/fetuses that are technically most accessible are chosen
   • The fetus overlying the internal os is avoided (rarely selected)
   • If a monochorionic pair exists, that pair is usually selected for reduction together (KCl cannot be used for one twin of a monochorionic pair)
4. Under continuous ultrasound guidance and strict sterile technique:
   • A 22-gauge needle is inserted transabdominally into the thorax of the targeted fetus
   • 2-3 mL of potassium chloride (KCl) is injected intracardiac/intrathoracic
   • Asystole (cardiac standstill) is observed for at least 3 minutes to confirm fetal demise
5. Procedure is repeated for additional fetuses using a new needle (or occasionally the same needle)
6. Post-procedure ultrasound at 1 hour and 1 week to confirm:
   • Demise of reduced fetuses
   • Viability and cardiac activity of retained fetuses

Transvaginal Approach

• Reserved for rare situations where target fetuses cannot be safely accessed transabdominally
• Associated with significantly higher loss rates (12% vs 5% transabdominal)
• Hence, the transabdominal route is strongly preferred

Target Number (Finishing Number)

• Most higher-order multiples are reduced to twins - this is the most common finishing number
• Reduction to singleton is increasingly performed (patient preference, especially after years of infertility); loss rates 2-4% vs 4-6% for reduction to twins
• Optimal finishing number appears to be twins, balancing loss rates and perinatal outcomes

Outcomes and Loss Rates

International Collaborative Data (>3500 pregnancies):

• Loss rates have fallen over time from 8% to 5%, reflecting a learning curve effect
• Risk of very preterm delivery (25-28 weeks) decreased from 6% to 1% as finishing number decreased
• For fetuses that reach viability after MFPR: 85-90% are born at ≥32 weeks, with only 3-5% born between 25-28 weeks

MFPR in Triplets (Meta-analysis, 24 studies):

• MFPR of triplets to twins significantly reduces preterm birth at <32 weeks (11% vs 29%) with no significant increase in miscarriage rates

Post-Procedure Care

• Close observation for complications of multiple gestation
• Serial ultrasound for fetal growth - increased risk of IUGR after MFPR
• Monitor for chorioamnionitis, preterm labour, PPROM
• Amniocentesis may be offered 4 weeks after MFPR for karyotyping of surviving fetuses (does not appear to increase loss risk)
• Psychological support - strongly recommended:
  • 70% of women demonstrate grief reactions after MFPR
  • 84% describe the procedure as very stressful
  • Psychological counselling should be offered routinely

Complications

Ethical and Counselling Considerations

• FIGO position: "For multiple pregnancy higher than twins, it may be considered ethically preferable to reduce the number of fetuses rather than to do nothing"
• ACOG/SMFM (2017): Support MFPR; recognize that reducing pregnancy decreases spontaneous loss rates and complications for all multifetal pregnancies; offer an ethical framework for obstetricians
• ASRM: More neutral - "MFPR appears associated with reduced prematurity risk, though true benefit is difficult to enumerate"

Key counselling points:

1. MFPR is not the same as abortion - the goal is to improve survival and health of remaining fetuses
2. The procedure involves the deliberate death of one or more viable fetuses - couples must understand and accept this
3. Options of expectant management vs. MFPR with their respective risks must be discussed in detail
4. Religious, cultural, and personal values must be respected
5. The decision must be individualized - a woman must weigh the obligate death of one fetus + procedure-related loss risk against a 2-3 fold reduction in very preterm birth risk
6. Psychological support throughout the process is essential

Summary

Stem Cell Banking

Definition

What Are Stem Cells?

1. Self-renewal - ability to divide and replicate themselves indefinitely
2. Differentiation - ability to develop into specialised cell types

Classification by Potency:

Types of Stem Cells Relevant to Banking:

1. Hematopoietic Stem Cells (HSCs) - found in cord blood; give rise to all blood cells (RBCs, WBCs, platelets) and immune cells
2. Mesenchymal Stem Cells (MSCs) - found in cord tissue (Wharton's jelly); can differentiate into bone, cartilage, fat, muscle; have immunomodulatory properties
3. Embryonic Stem Cells (ESCs) - derived from inner cell mass of blastocyst; pluripotent; ethically controversial
4. Induced Pluripotent Stem Cells (iPSCs) - adult somatic cells reprogrammed to a pluripotent state using transcription factors (Oct4, Klf4, Sox2, cMyc - Yamanaka factors, 2006); bypasses ethical concerns of ESCs

Sources of Stem Cells for Banking

Umbilical Cord Blood - Why It Is Important

Advantages of UCB over Bone Marrow:

1. Non-invasive collection - no risk to mother or baby
2. Collected at birth - readily available; no donor recruitment needed
3. Immediately available - reduces time to transplantation (banked in advance)
4. Greater HLA tolerance - allows some degree of HLA mismatch (up to 2-antigen mismatch) without severe graft-versus-host disease (GvHD)
5. Lower risk of GvHD - cord blood lymphocytes are immunologically naive
6. Lower risk of transmissible infection - young donor
7. Less stringent HLA matching required compared to bone marrow

Disadvantages of UCB:

1. Limited cell dose - small volume (40-150 mL); insufficient for adults (weight >50 kg)
2. Slower engraftment - delayed neutrophil and platelet recovery
3. Cannot collect additional cells from the same donor if needed
4. Failed or delayed engraftment - low HPC dose leads to increased morbidity/mortality
5. One-time collection opportunity

Collection of Cord Blood

Timing:

• Collected immediately after delivery (before or after placental delivery)
• Can be collected in utero (placenta still in place) or ex utero (after placental delivery)
• In utero collection typically yields a larger volume

Technique:

1. After delivery of the baby, the umbilical cord is clamped and cut
2. The cord vein is cannulated using a sterile needle and blood collection bag
3. Gravity drains blood from the cord and placenta into the collection bag
4. Volume typically: 40-150 mL (experienced centers)
5. Collections <40 mL are usually discarded (inadequate)
6. Approximately 4-11 × 10⁸ nucleated cells are harvested
7. Dedicated trained staff in the delivery room improves volume collected and reduces contamination risk

Processing:

• The collected blood is not usually further volume-processed (unlike bone marrow)
• Frozen directly with DMSO (dimethyl sulfoxide) as cryoprotectant
• Stored in liquid nitrogen at -196°C
• Shelf life: potentially indefinite when properly stored (some banks claim 25+ years)

Maternal screening before storage:

• Serological tests for HIV, Hepatitis B, Hepatitis C, HTLV, CMV, syphilis
• NAT (Nucleic Acid Testing) on maternal sample
• Bacteriologic testing on cord blood unit
• Screening for genetic diseases in mother/family
• HLA typing of the unit

Types of Cord Blood Banks

1. Public Cord Blood Banks

• Cord blood is donated by the family after birth
• The family relinquishes ownership; the unit is listed in national/international registries
• Available to any matched recipient worldwide
• Free of cost to the family
• Units are HLA-typed and made searchable for unrelated donor transplants
• Regulated by government bodies (FDA in USA; ICMR in India; HTA in UK; TGA in Australia)
• Certified by FACT-NetCord standards
• Approximately 9% of allogeneic transplants (2012-2016) utilized cord blood HPCs

• Increases the donor pool for unrelated transplants
• Helps patients without HLA-matched bone marrow donors
• No cost to family
• Contributes to public health

• Family cannot retrieve the donated unit
• No guarantee of availability or match for the donor family

2. Private (Family) Cord Blood Banks

• Cord blood stored exclusively for the donor family (child or compatible family member)
• Family retains 100% ownership
• Acts as "biological insurance"
• Annual storage fees apply (typically USD 100-300/year + initial processing fee USD 1500-2500)
• Regulated like public banks but operated as for-profit entities

• Guaranteed availability for the child
• Available for HLA-compatible sibling or family member
• No risk of unavailability when needed

• Expensive - not accessible to all families
• Very low probability of personal use (estimated 1 in 2500 to 1 in 200,000 chance the stored unit will be used by the donor child)
• Risk of the bank closing or going out of business
• The child most likely to need it (for inherited diseases) may be affected in the stored cells themselves

3. Hybrid / Directed Banks (Emerging)

• Family-directed storage while the unit is also HLA-typed and listed in the national registry
• If the child does not need it, the unit can be released to a matched unrelated recipient
• Increases diversity of cord blood units in public registries

Diseases Treatable with Cord Blood Stem Cell Transplantation

Established (Well-proven) Indications:

• Acute lymphoblastic leukaemia (ALL)
• Acute myeloid leukaemia (AML)
• Chronic myeloid leukaemia (CML)
• Myelodysplastic syndromes (MDS)
• Hodgkin and Non-Hodgkin lymphoma
• Neuroblastoma
• Retinoblastoma

• Aplastic anaemia
• Fanconi anaemia (first disease treated with UCB, 1989)
• Thalassaemia major - curative via allogeneic UCB transplant
• Sickle cell disease
• Severe combined immunodeficiency (SCID)
• Hurler's syndrome (MPS I) and other metabolic storage diseases
• Diamond-Blackfan anaemia
• Wiskott-Aldrich syndrome
• Chronic granulomatous disease

Investigational / Emerging Applications (clinical trials):

• Cerebral palsy (autologous UCB infusion - promising early results)
• Type 1 diabetes mellitus
• Autism spectrum disorder
• Acquired hearing loss (autologous UCB)
• Hypoxic-ischaemic encephalopathy (neonatal)
• Multiple sclerosis
• Cardiovascular disease (MSCs)
• Spinal cord injury
• Parkinson's disease
• Liver cirrhosis

Regulatory Framework

Induced Pluripotent Stem Cells (iPSCs) - A Special Mention

• Oct4, Klf4, Sox2, c-Myc (Yamanaka factors)

• iPSCs can potentially be generated from banked cord blood cells in the future
• Creates the prospect of patient-specific, autologous stem cells for any disease
• Eliminates rejection and GvHD concerns

Ethical Considerations

1. Public vs. private banking: Medical societies (ACOG, AAP, ICMR) generally favour public donation over private banking for most families, as it benefits the public and the probability of personal use is very low
2. Misleading marketing by private banks - overpromising future uses
3. Embryonic stem cell research - ethically controversial (requires destruction of embryos)
4. Equity and access - private banking is expensive and accessible mainly to affluent families
5. Consent - informed consent from the mother is mandatory for cord blood collection
6. Conflict of interest - healthcare providers must not financially benefit from recommending private banks

Position of Medical Bodies

• AAP (American Academy of Pediatrics): Supports public donation; does not recommend routine private banking unless a first-degree family member has a condition known to benefit from stem cell transplantation
• ACOG: Supports public cord blood banking; private banking may be considered when there is a family history of disease treatable by UCB transplantation
• ICMR (India): Regulates both public and private banks; supports public banking; calls for honest counselling about limitations of private banking
• FIGO: Supports public cord blood banking

Summary Table

Key Exam Points

1. First clinical use: Gluckman et al. 1989 - Fanconi anaemia patient cured with sibling cord blood
2. Collection volume: 40-150 mL; <40 mL discarded
3. Cryopreservation: DMSO + liquid nitrogen at -196°C
4. Advantage over bone marrow: 2-antigen HLA mismatch tolerated; less GvHD; immediately available
5. Major limitation: Low cell dose - insufficient for adults; slower engraftment
6. Yamanaka factors: Oct4, Klf4, Sox2, c-Myc (Nobel Prize 2012)
7. AAP/ACOG position: Favour public over private banking for routine cases
8. COBLT study: 55% event-free survival (malignant) and 78% (non-malignant) at 2 years

Stem Cell Therapy in Obstetrics and Gynaecology

Introduction

Types of Stem Cells Used in Reproductive Medicine

Mechanisms of Action of MSCs

1. Secretion of growth factors - VEGF (angiogenesis), IGF-1, HGF, EGF - promote tissue repair and regeneration
2. Anti-inflammatory effects - suppress pro-inflammatory cytokines (TNF-α, IL-1β, IL-6); increase anti-inflammatory IL-10, TGF-β
3. Anti-fibrotic effects - inhibit TGF-β1/Smad3 signalling; reduce matrix metalloproteinase (MMP) dysregulation; reduce fibrosis and scar formation
4. Pro-angiogenic effects - stimulate new blood vessel formation; improve endometrial vascularity
5. Immunomodulation - suppress T-cell, NK cell, and dendritic cell activity; relevant in implantation failure and autoimmune POI
6. Exosome-mediated repair - MSC-derived exosomes carry microRNAs (miRNAs) that regulate gene expression in target cells
7. Direct differentiation - into endometrial cells, granulosa cells, oocyte-like cells (less well established)

GYNAECOLOGICAL APPLICATIONS

1. Asherman's Syndrome (Intrauterine Adhesions / Thin Endometrium)

• Bone Marrow-Derived HSCs (CD133+ cells): Mobilised using G-CSF (5 mcg/kg/day x 4-5 days); CD133+ cells harvested; infused into uterine arteries via intrauterine artery catheterisation
  • Results: Significant increase in endometrial thickness; improved menstrual flow; documented pregnancies
• Bone Marrow MSCs (BMSCs): Mobilised with G-CSF; delivered intra-arterially or hysteroscopically
• Menstrual Blood MSCs (MenSCs): Promote endometrial cell proliferation via ERK1/2 and JNK signalling; upregulate cyclin D1 and cyclin E; reduce fibrosis via STAT3/Smad pathway modulation
• Endometrial MSCs (eMSCs): Derived from the basalis layer; directly contribute to endometrial regeneration

• Increased endometrial thickness (≥7 mm achieved in many treated patients)
• Improved menstrual pattern
• Successful pregnancies reported in previously infertile women
• Rodriguez-Eguren et al. systematic review (Hum Reprod Update 2024) confirms regenerative therapies show promise for endometrial disorders

2. Premature Ovarian Insufficiency (POI) / Premature Ovarian Failure (POF)

• Bone Marrow MSCs / BMSCs: Injected into ovarian tissue (transvaginal ultrasound-guided); dosing: 2, 5, or 10 million cells in 100 μL per ovary
  • Goal: stimulate follicular recruitment; restore hormonal function
• UC-MSC exosomes: Human umbilical cord MSC-derived exosomes have been shown to facilitate ovarian renovation in chemotherapy-induced POI in animal models (PMID: 37564988)
• Amniotic Epithelial Stem Cells: Alleviate autoimmune POI by targeting granulosa cells via AKT/ERK signalling pathways
• Adipose-Derived MSCs: Improve ovarian reserve markers (AMH, AFC)
• iPSC-derived oocytes: Experimental - iPSCs have been successfully differentiated into oocyte-like cells in vitro

• MSCs home to the damaged ovary
• Secrete paracrine factors that stimulate follicular granulosa cell survival and proliferation
• Suppress autoimmune inflammation (relevant in autoimmune POI)
• Reduce oxidative stress; improve follicular microenvironment

• Resumption of menstruation in some patients
• Improvement in FSH, AMH, and antral follicle count
• World's first baby born via ovarian stem cell therapy in a perimenopausal woman aged 45 (Gupta et al., 2018)

3. Endometriosis

• MSCs used not to stimulate endometriosis but to correct the underlying immune dysregulation and inflammation that drives it
• MSCs reduce pro-inflammatory cytokines; regulate NK cell activity; suppress endometriotic lesion growth via immunosuppression
• Anti-fibrotic effects: Reduce peritoneal adhesion formation
• Endometrial stem cell dysregulation hypothesis: Abnormal migration of endometrial stem cells to ectopic sites may be a cause of endometriosis; understanding this is key
• MenSCs and eMSCs in preclinical models show paracrine anti-inflammatory effects on ectopic endometrial lesions

4. Polycystic Ovarian Syndrome (PCOS)

• MSCs reduce androgen levels; improve insulin sensitivity; restore ovulation
• Mechanisms: Anti-inflammatory and anti-oxidant effects; modulation of ovarian steroidogenesis; improvement of granulosa cell function
• Adipose-derived MSCs: Show promising results in PCOS animal models
• MSC therapy can provide a holistic treatment approach addressing both metabolic and reproductive aspects of PCOS

5. Recurrent Implantation Failure (RIF) and Recurrent Miscarriage

• Endometrial MSC instillation before embryo transfer in IVF
• PRP (Platelet-Rich Plasma): Contains growth factors that stimulate endometrial MSC activity; intrauterine PRP infusion improves endometrial receptivity (analogous to stem cell activation)
• Autologous peripheral blood mononuclear cells (PBMC) instillation - stimulates endometrial immune tolerance (Treg cells)
• MSC-derived exosomes improve endometrial receptivity markers (integrin αvβ3, LIF, HOXA10)

• Improved implantation rates in thin endometrium patients
• Ongoing clinical trials show promising live birth rate improvement

OBSTETRIC APPLICATIONS

6. Preeclampsia

• MSCs have potent anti-inflammatory and pro-angiogenic properties
• In animal models: MSC infusion reduces hypertension, proteinuria, and IUGR in preeclampsia models
• Mechanisms:
  • Improve placental trophoblast invasion
  • Restore spiral artery remodelling
  • Reduce anti-angiogenic factors (sFlt-1, sEng)
  • Increase VEGF and PlGF (pro-angiogenic)
  • Suppress systemic maternal inflammatory response
• Adipose-derived and bone marrow MSCs have shown the most evidence in preclinical models

7. Fetal Stem Cell Therapy (In Utero Stem Cell Transplantation)

• Fetal HSC transplantation in utero for severe inherited haematological/immunological conditions
• Donor cells engraft in fetal liver/bone marrow; establish mixed chimerism
• Fetal tolerance may persist postnatally (beneficial for postnatal booster transplants)

• Alpha-thalassaemia major (hydrops fetalis) - HSC transplantation
• Severe combined immunodeficiency (SCID)
• Sickle cell disease
• Fanconi anaemia
• Lysosomal storage disorders (Hurler's, Gaucher's)
• Osteogenesis imperfecta - in utero MSC transplantation; MSCs differentiate into osteoblasts and partially correct bone fragility

• Clinical trials (NCT programmes) have shown safety
• MSC engraftment in fetal bone tissue demonstrated
• Partial improvement in fracture rate and linear growth

8. Intrauterine Growth Restriction (IUGR) and Placental Insufficiency

• MSC-derived exosomes and growth factor secretion may improve placental function in IUGR
• Improve uteroplacental blood flow; stimulate trophoblast invasion
• Primarily preclinical; human studies pending

9. Post-partum Cardiomyopathy (Peripartum Cardiomyopathy)

• Cardiac stem cell therapy / MSC infusion for peripartum cardiomyopathy (PPCM) - a severe, life-threatening condition
• MSCs improve cardiac function, reduce fibrosis, and promote angiogenesis
• Case reports and early trials show benefit
• Not strictly OBG, but directly relevant to obstetric care

10. Gynaecological Oncology

• Stem cell-targeted therapy: Cancer stem cells (CSCs) in cervical cancer maintain tumour growth and mediate resistance; targeting CSCs (CD44+/CD24- population) is a therapeutic strategy
• MSC as drug delivery vehicles: MSCs naturally home to tumour sites; engineered MSCs can deliver anticancer payloads (TRAIL, oncolytic viruses) directly to cervical/ovarian cancer

• Ovarian cancer stem cells drive chemoresistance (to platinum/taxol)
• Targeting CSC markers (CD133, CD44, EpCAM) is investigational
• MSCs used as delivery vehicles for anticancer agents to ovarian tumours

• Endometrial cancer stem cells (ECSCs) contribute to recurrence; targeting via differentiation therapy or immune modulation

Sources of MSCs Used in Reproductive Medicine

Routes of Stem Cell Delivery

Current Status and Evidence

Limitations and Challenges

1. Safety concerns: Risk of malignant transformation of transplanted stem cells; tumorigenicity of ESCs/iPSCs
2. Immune rejection: Allogeneic MSCs may be rejected; autologous cells preferred but limited
3. Standardisation: No standard protocols for cell isolation, culture, dose, or delivery route
4. Limited cell dose and survival: Transplanted cells often fail to engraft long-term
5. Ethical concerns: ESC use requires embryo destruction; iPSC reprogramming still imperfect
6. Regulatory hurdles: Stem cell therapies require rigorous clinical trial data before approval
7. Cost: Expensive; not currently covered by insurance/health systems
8. Lack of long-term data: Long-term safety and efficacy data from human trials are limited
9. Commercial exploitation: Unregulated clinics offering unproven stem cell treatments (cautioned against by ICMR, FDA)

Future Prospects

1. Exosome-based therapy - cell-free approach using MSC-derived exosomes; avoids cell viability issues
2. Gene-edited iPSCs - patient-specific cells corrected of genetic defects (e.g., for haemoglobinopathies)
3. 3D bioprinting with stem cells - bioengineered uterus/ovarian tissue
4. Ovarian tissue banking + stem cell-assisted reconstitution - fertility preservation in cancer patients
5. Artificial ovary - decellularised ovarian scaffold + patient's own stem cells
6. Endometrial organoids from stem cells for modelling implantation failure
7. Targeted CSC therapy in gynaecological cancers

Summary Table

Ethics and Medico-Legal Issues in Obstetrics

Introduction

I. PRINCIPLES OF MEDICAL ETHICS (BEAUCHAMP AND CHILDRESS)

• Confidentiality - patient information must not be disclosed without consent
• Veracity (honesty) - truthful communication with patients
• Fidelity - keeping promises made to the patient

II. ETHICAL ISSUES SPECIFIC TO OBSTETRICS

1. Informed Consent in Obstetrics

• Voluntary - free from coercion or undue influence
• Informed - patient has received adequate information about:
  • Nature of the procedure
  • Risks and benefits
  • Alternatives available
  • Consequences of refusing treatment
• Competent - patient has decision-making capacity
• Documented - in writing, with signature

• Emergency situations: When a patient cannot consent (unconscious, in shock) and delay would cause serious harm, the doctor may proceed under the doctrine of implied consent (emergency exception)
• Minors: In India, consent of parent/guardian is required for minors (<18 years); however, in case of MTP, a minor's own consent (without guardian) is respected (MTP Act 2021 amendment)
• Caesarean section consent: Must explain that caesarean is a major surgery with real risks; cannot be performed on a competent patient without consent, even to save the fetus
• Routine obstetric procedures: Vaginal examinations, episiotomy, and instrumental deliveries all require specific consent

2. Maternal-Fetal Conflict

• Patient refuses recommended caesarean section (e.g., for placenta praevia, fetal distress)
• Patient refuses blood transfusion (Jehovah's Witness) despite life-threatening haemorrhage; refusal may jeopardise fetal welfare
• Patient refuses treatment for drug/alcohol use that is harming the fetus
• Patient insists on vaginal delivery after previous uterine rupture

• The pregnant woman's autonomy is paramount
• Obstetricians should refrain from performing procedures that are unwanted by a pregnant woman
• Court orders to force treatment on competent pregnant women raise serious ethical concerns:
  • Forced treatment violates autonomy in ways not required of any other competent adult
  • Creates precedent that pregnancy forfeits a woman's right to bodily autonomy
  • Adversely affects the physician-patient relationship
  • Inconsistency: competent adults can refuse therapy in all other situations
• The obstetrician should seek a negotiated solution - identifying duties to both patients and seeking balance - rather than taking sides

3. Abortion / Medical Termination of Pregnancy - Ethical Issues

• Respect for fetal life vs. woman's reproductive autonomy
• Religious and cultural values vs. medical need
• Societal interest vs. individual rights

• Pro-life: The fetus has moral status from conception; abortion is morally impermissible
• Pro-choice: The woman's right to bodily autonomy overrides fetal moral status at least until viability
• Moderate positions: Fetal moral status increases progressively with gestational age; early abortion may be permissible but late abortion requires stronger justification

• Not required to perform abortions against their moral/religious convictions (conscientious objection)
• However, must refer the patient to a willing provider promptly and without delay
• Must not impose personal values on patients
• Must provide factually accurate, non-directive information

4. Genetic Testing and Prenatal Diagnosis - Ethical Issues

• Non-directive counselling: Genetic counsellors must present information without directing the patient's choice
• Right not to know: Patient has the right to decline prenatal genetic testing
• Selective termination for genetic abnormality: Acceptable for lethal conditions (anencephaly, trisomy 18); ethically more complex for conditions like Down syndrome
• Sex-selective termination: Ethically and legally unacceptable (see PCPNDT Act)
• Incidental findings: Discovery of unexpected genetic information (e.g., non-paternity, carrier status) raises confidentiality issues
• Disability discrimination: Termination for minor disabilities is ethically controversial

5. Confidentiality in Obstetrics

• All obstetric information is strictly confidential
• Cannot be disclosed without patient consent except:
  • When required by law (notifiable diseases, birth/death registration)
  • To prevent serious harm to a third party (rare)
  • Statutory reporting (stillbirths, maternal deaths - MDSR)
• Partner disclosure: If patient is HIV positive, the obstetrician faces a conflict between confidentiality (patient does not want partner told) and duty to warn (partner at risk)
• Medical records: Patient has the right to access her own records

6. Surrogate Motherhood - Ethical Issues

• Altruistic surrogacy (permitted in India under Surrogacy (Regulation) Act 2021): only close relative can be surrogate
• Commercial surrogacy now banned in India (previously legal)
• Ethical concerns:
  • Exploitation of economically vulnerable women
  • Commodification of reproduction
  • Legal parentage disputes
  • What happens if surrogate changes her mind?
  • What if intended parents refuse to accept the child (e.g., disabled)?

7. Assisted Reproductive Technology (ART) - Ethical Issues

• Multiple embryo transfer: Creates higher-order multiple pregnancies; ethical to limit to 1-2 embryos?
• Embryo storage and disposal: Frozen embryos - who decides their fate on divorce/death of partner?
• Pre-implantation genetic diagnosis (PGD): Selection of embryos based on genetics - where does selection end?
• Donor gametes: Right of donor-conceived children to know their genetic origin
• Post-menopausal pregnancies: Ethically controversial - child may be orphaned early
• Regulated in India by ART (Regulation) Act, 2021

III. MEDICO-LEGAL ISSUES IN OBSTETRICS

1. Medical Negligence in Obstetrics

1. Duty of care existed (doctor-patient relationship)
2. Breach of duty - standard of care was not met
3. Causation - the breach caused the harm (damage)

• Accurate, contemporaneous medical records are the first line of defence in litigation
• "If it is not documented, it was not done"
• Partogram, CTG strips, operation notes, consent forms must be properly maintained

2. PCPNDT Act (Pre-Conception and Pre-Natal Diagnostic Techniques Act, 1994)

• Use of any technique (ultrasound, amniocentesis, CVS) to determine the sex of a fetus before or after conception
• Communication of sex of the fetus in any form
• Sex-selective abortion

• All ultrasound machines/clinics must be registered with the appropriate authority
• Written consent of the woman is mandatory before any prenatal diagnostic procedure
• Form F must be filled for every ultrasound scan (name, address, indication)
• Prohibition: No person shall conduct sex-selective abortion
• Communication of sex is banned by all persons including clinician, radiologist, and technician
• Sting operations permitted by the competent authority

• First offence: 3 years imprisonment + Rs. 10,000 fine
• Second and subsequent offences: 5 years imprisonment + Rs. 50,000 fine
• Name removed from medical register
• Equipment may be seized and sealed

3. MTP Act (Medical Termination of Pregnancy Act, 1971) - Amended 2021

1. Continuance of pregnancy involves risk to life of pregnant woman
2. Risk of grave injury to physical or mental health
3. Pregnancy from rape or incest (presumed to cause grave mental injury)
4. Contraceptive failure - now applies to ALL women (not just married women - 2021 amendment)
5. Risk to health of existing children
6. Fetal abnormality - substantial abnormality incompatible with life or likely serious handicap

• Woman ≥18 years: only her own consent is required (no husband/partner consent needed)
• Woman <18 years or mentally ill: guardian consent required
• 2021 amendment: identity of woman must not be disclosed; strict confidentiality

• Registered Medical Practitioner (RMP) with experience/training in gynaecology and obstetrics
• At a government hospital or a place approved under the MTP Act

4. Maternal Death Review and Reporting

• All maternal deaths must be reported to the state health authority
• Maternal Death Surveillance and Response (MDSR) is mandatory in India
• Audits of maternal deaths identify avoidable factors
• Withholding a maternal death from notification is a legal and ethical violation

5. Birth Registration and Certification

• Every live birth must be registered within 21 days (Registration of Births and Deaths Act 1969)
• Every stillbirth must be registered
• The birth certificate is a legal document; falsification is a criminal offence
• The doctor/midwife who attends the birth is responsible for registration

6. Stillbirth - Medico-Legal Aspects

• Definition in India (for registration): Baby born after 28 weeks with no sign of life
• Stillbirths must be registered separately from live births
• A stillbirth is not a legal death (no death certificate needed)
• Medical certificate of stillbirth (Form 4/5) must be issued
• Unexplained or suspicious stillbirth may require medico-legal investigation

7. The Consumer Protection Act and Obstetrics

• The Consumer Protection Act 1986 (amended 2019) classifies medical services as "services"
• Patients are "consumers" who can file complaints for deficiency in service (including negligence)
• Cases are heard before Consumer Disputes Redressal Commissions (District/State/National)
• Simpler, cheaper, and faster than civil courts for the patient
• Does not require proof of criminal intent - only negligence/deficiency in service

8. Rights of the Pregnant Woman - A Summary

IV. SPECIFIC MEDICO-LEGAL SCENARIOS

Scenario 1: Patient Refuses Emergency Caesarean

1. Assess competency of the patient
2. Ensure she is fully informed of consequences
3. Involve family (with her permission) in counselling
4. Document all discussions
5. Seek ethics committee input if time permits
6. Do not perform the procedure without consent - forced surgery = assault in law
7. Document refusal with witnesses; patient must sign a refusal form

Scenario 2: Jehovah's Witness with PPH

1. Respect refusal of blood transfusion (autonomous adult decision)
2. Discuss all alternatives: cell salvage, iron infusion, coagulation factor concentrates, tranexamic acid, uterotonics
3. Document detailed consent and refusal
4. Involve haematology and anaesthetics early
5. If patient loses consciousness and becomes incompetent, legal position changes
6. For minor children of JW parents, courts may override parental refusal

Scenario 3: Discovery of Female Feticide Request

• The doctor is legally obligated to refuse
• Must not reveal sex of fetus
• Must complete Form F accurately
• If pressure is applied, the doctor should report to the appropriate authority
• The doctor who complies is equally liable under PCPNDT Act

V. ETHICAL FRAMEWORK FOR DECISION-MAKING

1. Gather facts: Medical facts, patient's values, family situation
2. Identify stakeholders: Mother, fetus, family, healthcare team
3. Apply ethical principles: Which principles are at stake? Which takes priority?
4. Consider legal framework: Is there a relevant statute (MTP Act, PCPNDT Act)?
5. Explore all options: Are there alternatives that avoid the conflict?
6. Consult: Ethics committee; senior colleagues; legal advice if needed
7. Document: Every discussion, decision, and its rationale
8. Act: Implement the decision with ongoing reassessment

Summary

Measures by Telangana Government to Reduce Caesarean Section Rate

Background: The Problem

Key Statistics (NFHS-6, 2023-24):

• Telangana's C-section rate has risen from 60.7% (NFHS-5, 2019-21) to 62.2% (NFHS-6) - moving in the wrong direction
• Neighbouring Andhra Pradesh has the second-highest rate at 52.2%
• WHO recommended rate: 10-15%
• Telangana's target (Telangana Rising 2047): Reduce from 55-62% to <15%

Why Is the Rate So High in Telangana? (Root Causes)

Provider-side factors:

• Financial incentives in private hospitals - C-sections are more profitable than vaginal deliveries
• Fear of litigation - doctors prefer C-section to avoid blame for a bad vaginal delivery outcome
• Convenience scheduling - elective C-sections during daytime/weekdays
• Insufficient skilled manpower for managing prolonged labour (no patience for watchful waiting)
• Inadequate training in operative vaginal delivery (vacuum/forceps)
• Lack of proper labour room protocols

Patient-side factors:

• Patient/family demand for C-section ("too posh to push" phenomenon)
• Fear of pain and labour
• Misconceptions about C-section being "safer"
• High literacy rates in Telangana correlate paradoxically with higher C-section demand

System-side factors:

• Inadequate regulation of private hospitals
• Lack of transparency in C-section data
• 98.8% institutional delivery rate - nearly all births occur in hospitals, increasing exposure to medicalised birth
• Absence of robust midwifery model in private sector

Measures Taken / Proposed by Telangana Government

1. Inquiry Committee for Unwarranted C-sections

• The Telangana government constituted a four-member inquiry committee to investigate unwarranted/unnecessary C-section surgeries, particularly in government hospitals following reports of complications (five women developing complications post-C-section at a government hospital)
• Mandate: investigate causes, identify systemic failures, and recommend corrective action

2. Mandatory Public Display of C-section Data

• Both public and private hospitals directed to publicly display their C-section delivery rates
• Rationale: Transparency and public accountability - allows patients to make informed choices about where to deliver
• A hospital with an 80%+ C-section rate displayed on its board creates reputational pressure to reduce unnecessary procedures

3. Robson Ten-Group Classification System - Mandatory Audits

• The Telangana Rising 2047 Vision Document mandates implementation of systematic Robson classification audits in both public and private facilities
• Robson Classification categorises all deliveries into 10 mutually exclusive, totally inclusive groups based on:
  • Parity (nulliparous/multiparous)
  • Onset of labour (spontaneous/induced/pre-labour caesarean)
  • Fetal presentation (cephalic/breech/transverse)
  • Gestational age (preterm/term)
  • Number of fetuses (singleton/multiple)
• Allows hospitals to identify which specific group is driving the high C-section rate
• The groups contributing most to Telangana's high rate are likely Group 1 (nulliparous, singleton, cephalic, term, spontaneous labour) and Group 5 (previous caesarean, singleton, cephalic, term)
• Target: Bring overall C-section rate closer to WHO-recommended levels over time

4. LaQshya (Labour Room Quality Improvement Initiative)

• National programme actively implemented in Telangana
• LaQshya focuses on:
  • Improving quality of care in labour rooms and maternity operation theatres
  • Respectful maternity care
  • Reducing avoidable interventions (including unnecessary C-sections)
  • Skilled birth attendant availability round-the-clock in all maternity OTs
  • Standard protocols for labour management
  • Evidence-based decision making during labour

5. Strengthening Midwifery and Skilled Birth Attendance

• Telangana Rising 2047 commits to:
  • Scaling nurse, midwife practitioner training
  • Expanding midwife-led continuity of care models
  • A strong midwifery cadre reduces unnecessary C-sections by providing skilled, confident management of normal labour
  • Midwife-led care models are associated with significantly lower C-section rates internationally

6. Maternity Operation Theatre Quality Standards

• Improving maternity OT quality standards with skilled birth attendants available 24×7
• Ensures that when a C-section IS genuinely needed, it can be done safely and promptly
• Reduces defensive C-sections done "just in case" due to lack of emergency backup

7. Regulation of Private Hospitals

• Private hospitals in Telangana account for the bulk of C-sections (83.9% of private hospital deliveries)
• Government measures include:
  • Mandatory registration and reporting of mode of delivery data
  • Clinical audit requirements for hospitals with high C-section rates
  • Penal action against hospitals performing unwarranted C-sections
  • Tying empanelment under government insurance schemes (Aarogyasri) to appropriate C-section rates

8. Janani Shishu Suraksha Karyakram (JSSK) Integration

• JSSK provides free deliveries (including C-sections when needed) in public hospitals
• Encouraging women to deliver in public institutions where C-section rates are monitored and controlled
• Removes financial incentive for unnecessary C-sections in public facilities
• Reduces out-of-pocket expenditure and patient vulnerability to persuasion for C-section

9. Pradhan Mantri Surakshit Matritva Abhiyan (PMSMA)

• Monthly antenatal camps for high-risk identification
• Identifies true high-risk pregnancies early, allowing proper planning
• Reduces late, panic-driven C-sections in the absence of proper antenatal planning

10. Community Awareness and Demand Generation

• Counselling of pregnant women during antenatal visits about the safety, normalcy, and benefits of vaginal delivery
• ASHA and ANM-led awareness campaigns to dispel myths that C-section is safer or preferable
• Addressing the social norm in Telangana where C-section has become a status symbol in some communities

11. IMI 5.0 (Intensified Mission Indradhanush)

• Linked to maternal health improvement
• Convergent programme addressing the broader determinants of maternal health

Summary of Targets (Telangana Rising 2047 Vision)

National Framework Supporting These Measures

Challenges in Implementation

1. Private sector regulation is difficult - private hospitals resist government oversight
2. Deep-rooted financial incentives - C-sections are significantly more profitable
3. Cultural demand from patients and families for C-sections
4. Medico-legal fear among doctors driving defensive C-sections
5. Lack of skilled birth attendants for managing complex labour
6. Shortage of qualified midwives in India (unlike UK/Netherlands where midwifery models reduce C-sections)
7. Even public hospital C-section rate (48.1%) is nearly 3 times the national government hospital average (16.9%) - suggesting systemic rather than purely private-sector problem

Key Points to Remember

1. Telangana has the highest C-section rate in India at 62.2% (NFHS-6, 2026) - more than double the national average
2. Private hospitals account for 83.9% C-sections vs. 48.1% in government hospitals (both alarming)
3. WHO recommended rate: 10-15%; Telangana's target: <15%
4. Key measures: Inquiry committee, mandatory data display, Robson classification audits, LaQshya, midwifery strengthening, private hospital regulation
5. The Robson Ten-Group Classification is the cornerstone of identifying and reducing unnecessary C-sections
6. Transparency (public display of data) and accountability (audits) are the most potent levers